Back to Awarded Treatment Trials
Awarded Trial: 02-STN-001
Grant ID
02-STN-001
Illness
Schizophrenia
Primary Drug/Intervention
Amoxapine
Primary Dosage
up to 200 mg
Secondary Drug Intervention
Olanzapine
Secondary Dosage
up to 15mg
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Terminated
Investigator
Fitzgerald
Sample Size
10
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANSS, MADRS, Barnes-akathisia
Results
Ten patients were randomized, all 5 of the patients in the olanzapine group completed the study and they exhibited significant improvements on positive, negative and general symptom ratings. None of the patients receiving amoxapine completed the study, and 4 of 5 withdrew due to lack of efficacy. Because of the high withdrawal rate in the amoxapine group randomization was terminated.
Publication
Fitzgerald PB, Filia S, De Castella A, McBain N, Kapur S, Kulkarni J. Amoxapine in schizophrenia: a negative double-blind controlled trial. J Clin Psychopharmacol. 2004 Aug;24(4):448-50.
Link
http://www.ncbi.nlm.nih.gov/pubmed/15232339
PI Name
Paul Fitzgerald
Degree
MD
Center
Alfred Psychiatric Research Centre
Institution
DAMHS
Address
P.O. Box 856, Dandenong
City or Town
N/A
State or Province
N/A
Zip or Postal Code
3175
Country
Australia
Email Address
p.fitzgerald@alfred.org.au